Publications
Publications From: Donald E. Cutlip, MD
The SIRIUS STudy: 5-Year Outcomes
The Adoption of the 2000 European Society of Cardiology and American College of Cardiology Guidelines on Acute Coronary Syndrome Eliminated the Gender Difference in First-Year Survival
Bench to Bedside: Thrombosis
Defining the Risk of Late Stent Thrombosis
Effect of Sirolimus-Eluting Stents versus Bare-Metal Stents on Outcomes Related to Restenosis and Disease Progression in Remote Coronary Segments
Impact of Target Lesion Revascularization During the First year After Bare-Metal or Sirolimus-Eluting Stenting on Five-Year Cardiac Outcomes
Multi-Vessel Drug-Eluting Stenting and Impact of Diabetes Mellitus- A Report from the EVENT Registry
In-Hospital and 1-Year Outcomes among PCI Patients with Chronic Kidney Disease in the Era of Drug-Eluting Stents: A Report from the EVENT Registry
One-Year Clinical Outcomes of Sirolimus-Eluting vs. Paclitaxel-Eluting Stents in Unselected Patients: Results from the Multicenter EVENT Registry
Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007 Jun 5;115(22):2842-7.
Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis. 2009 Nov 17. [Epub ahead of print]
Claudication: exercise vs endoluminal revascularization (CLEVER) study update. J Vasc Surg. 2009 Oct;50(4):942-945.e2.
SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J. 2009 Oct;158(4):520-526.e2.
Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv. 2009 Oct;2(10):977-85.
Association between advanced Killip class at presentation and impaired myocardial perfusion...with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors. Am Heart J. 2009 Sep;158(3):416
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT...registry. JACC Cardiovasc Interv. 2009 Aug;2(8):767-75.
Five-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: eNDEAVOR I, first-in-human study. Catheter Cardiovasc Interv. 2009 Jul 13.
In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study. JACC Cardiovasc Imaging. 2009 Jul;2(7):858-68.
Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. JACC Cardiovasc Interv. 2009 Jun;2(6):498-503.
Clinical endpoints in transcatheter aortic valve implantation: a call to ARC for standardised definitions. EuroIntervention. 2009 May;5(1):29-31.
Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and...with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis. 2009 Apr 5.
Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol. 2009 Apr 28;53(17):1488-97.
Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of...Circulation. 2009 Feb 10;119(5):680-6.
In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT...registry. JACC Cardiovasc Interv. 2009 Jan;2(1):37-45.
Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents. Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System. Circulation. 2009 Jan 26.
Multivessel drug-eluting stenting and impact of diabetes mellitus-A report from the EVENT registry. Catheter Cardiovasc Interv. 2008 Dec 9.
A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv. 2008 Oct;1(5):524-32.
Identifying stent thrombosis, a critical appraisal of the academic research consortium (ARC) consensus definitions: a lighthouse and as a toe in the water. EuroIntervention. 2008 Aug;4 Suppl C:C39-44.
An introduction to "A critical appraisal of the safety concerns tempering the success of drug-eluting stents". EuroIntervention. 2008 Aug;4 Suppl C:C5-6.
A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. JACC Cardiovasc Interv. 2008 Jun;1(3):248-57.
Peter Zimetbaum MD, Jeffrey J. Popma MD, Laura Mauri MD, Joseph Massaro PhD, and Donald E. Cutlip MD
The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: rationale and methods. J Vasc Surg. 2008 Jun;47(6):1356-63.
The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: Rationale and methods. J Vasc Surg. 2008 Apr 24.
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008 Apr 23;299(16):1903-13.
Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation. 2008 Feb 12;117(6):790-7.
Prevalence and Prognostic Significance of Pre-Procedure Cardiac Troponin Elevation among Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Results from the EVENT Registry. Circulation 2008 (in press).
Drug eluting stents for ST-elevation myocardial infarction: risk and benefit J Thromb Thrombolysis. 2007 Dec;24(3):293-9.
Gender-specific outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2007 Nov 27;50(22):2111-6.
Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol. 2007 Oct 22;100(8B):56M-61M.
Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007 Oct 2;50(14):1299-304.
Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol. 2007 Sep 1;100(5):818-23.
Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease. Nephrol Dial Transplant. 2007 Sep;22(9):2578-85.
Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts.Circulation. 2002 Mar 19;105(11):1285-90.
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.
A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007 Mar 8;356(10):989-97.
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007 Mar 8;356(10):998-1008.
Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 Mar 8;356(10):1020-9.
Donald E. Cutlip MD, Laura Mauri MD, Kalon K.L. Ho MD, MSc, Ralph D'Agostino PhD, and Joseph Massaro PhD
